TB-500 vs BPC-157

Side-by-side comparison of TB-500, BPC-157 — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute TB-500 Thymosin Beta-4 Synthetic Analogue Recovery BPC-157 Body Protection Compound-157 Recovery
Basics
Molecular type Thymic Peptide AnalogueGastric Pentadecapeptide
Amino acids 4315
Molecular weight 4,921 Da1,419.5 Da
Half-life Long-acting (days)~4 hrs (SC)
Route(s) Subcutaneous, IntramuscularSubcutaneous, Intramuscular, Oral (research only)
Mechanism & Research
Primary mechanism TB-500's primary mechanism involves binding to G-actin (monomeric actin) through its conserved LKKTETQ sequence. By sequestering actin, it regulates cytoskeletal dynamics in ways that promote cell migration — a critical … BPC-157 exerts its primary effects through upregulation of the nitric oxide (NO) signalling pathway. By promoting NO synthase activity, it drives vasodilation and angiogenesis at injury sites, accelerating the delivery o…
Research status Research Compound Research Compound
Evidence summary TB-500 research spans cardiac regeneration, wound healing, hair follicle regeneration, and musculoskeletal repair. Most data is preclinical. Phase 1/2 trials with native Thymosin Beta-4 for cardiac indications have been … The majority of BPC-157 research is preclinical (animal and in vitro). No large-scale randomised controlled trials in humans have been published as of 2026. The FDA's 2024 assessment noted insufficient human safety and e…
Protocol & Dosing
Typical dose 5–10 mg per injection200–500 mcg per injection
Frequency 2x per week (loading), then weeklyOnce or twice daily
Duration 4–8 weeks4–12 weeks
Timing No specific timing requirementNear injury site when possible
Safety
Common side effects
  • Injection site reaction
  • Mild fatigue (transient)
  • Headache
  • Lethargy in first days
  • Injection site redness or bruising
  • Mild nausea (oral form)
  • Transient dizziness
  • Warmth at injection site
Contraindications
  • Active cancer (angiogenic activity)
  • Pregnancy
  • Platelet disorders or anticoagulant use
  • Active malignancy (theoretical growth stimulation concern)
  • Pregnancy (no safety data)
  • Concurrent anticoagulant therapy (caution)
Anti-doping Prohibited (WADA S2) Prohibited (WADA S0)
Deeper reading
Related peptides BPC-157, GHK-Cu, Thymosin Alpha-1 TB-500, GHK-Cu, KPV, Pentadeca Arginate
Full profile Read full TB-500 profile → Read full BPC-157 profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.